Wound healing and dermal regeneration in severe burn patients treated with NovoSorb® Biodegradable Temporising Matrix: A prospective clinical study

• Published in: Burns Vol. 48; no. 3; pp. 529 - 538
• Main Authors: Lo, Cheng Hean, Brown, Jason N., Dantzer, Eric J.G., Maitz, Peter K.M., Vandervord, John G., Wagstaff, Marcus J.D., Barker, Timothy M., Cleland, Heather
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.05.2022
• Subjects: Biodegradable polyurethane; Biodegradable Temporising Matrix; Burn; Burns - surgery; Cicatrix - etiology; Dermal matrix; Full-thickness burns; Humans; Polyurethanes - therapeutic use; Prospective Studies; Skin graft; Skin Transplantation - methods; Skin, Artificial; Wound Healing; ADE; AE; Full-thickness burns; CI; SSG; Biodegradable Temporising Matrix; Skin graft; Biodegradable polyurethane; Burn; SD; VSS; Dermal matrix; BTM; TBSA
• ISSN: 0305-4179; 1879-1409
• DOI: 10.1016/j.burns.2021.07.014

•Early autologous skin grafting may not be possible in severe burn patients.•NovoSorb® BTM is a 2 mm biodegradable polyurethane dermal regeneration template.•Four weeks may be necessary for NovoSorb® BTM integration prior to delamination.•NovoSorb® BTM seems resistant to infection, attributable to its synthetic nature.•Majority of wounds successfully closed with NovoSorb® BTM and split skin grafts. For extensive burns, autologous donor skin may be insufficient for early debridement and grafting in a single stage. A novel, synthetic polyurethane dermal template (NovoSorb® Biodegradable Temporising Matrix, BTM) was developed to address this need. The aim of this study was to evaluate use of BTM for primary dermal repair after deep burn injury. A multicentre, prospective, clinical study was conducted from September 2015 to May 2018. The primary endpoint was % split skin graft take over applied BTM at 7–10 days after grafting. Secondary endpoints included % BTM take, incidence of infection and adverse events, and scar quality to 12 months after BTM application. Thirty patients were treated with BTM and delayed split skin grafting. The % graft take had a mean of 81.9% and % BTM take had a mean of 88.6%, demonstrating effective integration of BTM. When managed appropriately, it was possible for BTM to integrate successfully despite findings suggestive of infection. Scar quality improved over time. These results provide additional clinical evidence on the safety and performance of BTM as an effective dermal substitute in the treatment of patients with deep burn injuries.